Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Rasagiline mesylate
Drug ID BADD_D01916
Description Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Indications and Usage For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.
Marketing Status approved
ATC Code N04BD02
DrugBank ID DB01367
KEGG ID D02562
MeSH ID C031967
PubChem ID 3052775
TTD Drug ID D06OMW
NDC Product Code 0378-1271; 57741-1900; 23155-746; 68546-229; 65035-133; 57741-2000; 65015-775; 55111-900; 66039-878; 23155-747; 0378-1270; 68546-142; 82245-0114
UNII LH8C2JI290
Synonyms rasagiline | N-2-propynyl-1-indanamine | AGN 1135 | AGN-1135 | TVP 1022 | TVP1022 | TVP-1022 | N-propargyl-1-aminoindan mesylate | rasagiline hydrochloride | TVP 101 | TVP-101 | 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride | Azilect
Chemical Information
Molecular Formula C13H17NO3S
CAS Registry Number 161735-79-1
SMILES CS(=O)(=O)O.C#CCNC1CCC2=CC=CC=C12
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Somnolence17.02.04.006; 19.02.05.003--
Stomatitis07.05.06.005--
Strabismus06.05.02.004; 17.17.01.009---
Stupor17.02.04.007; 19.02.05.004---
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tenosynovitis15.07.01.004---
Thrombocytosis01.08.02.001---
Thrombophlebitis24.01.02.001---
Tongue disorder07.14.01.002---
Tongue oedema07.14.02.007; 10.01.05.008; 23.04.01.009---
Tremor17.01.06.002--
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002---
Urinary incontinence17.05.01.008; 20.02.02.010--
Urinary retention20.02.02.011--
Urinary tract disorder20.08.01.001---
Urticaria10.01.06.001; 23.04.02.001--
Vaginal discharge21.08.02.002--
Vaginal haemorrhage21.08.01.001; 24.07.03.005--
Vaginal infection11.01.10.002; 21.14.02.002--
Vascular purpura01.01.04.007; 23.06.01.008; 24.07.06.011---
Ventricular extrasystoles02.03.04.007---
Ventricular fibrillation02.03.04.008--
Ventricular tachycardia02.03.04.010--
Vertigo04.04.01.003; 17.02.12.002--
Vestibular disorder04.04.02.001; 17.02.02.008--
Visual field defect06.02.07.003; 17.17.01.001---
Vomiting07.01.07.003--
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Weight decreased13.15.01.005--
The 8th Page    First    Pre   8 9 10    Next   Last    Total 10 Pages